| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | PARATEK PHARMACEUTICALS INC | 2,600,410 | 40,046,000 | 32.50% | ||
| 2 | JUNO THERAPEUTICS INCORPORATED | 1,229,512 | 23,176,000 | 18.81% | ||
| 3 | Egalet Corp | 2,889,926 | 22,108,000 | 17.94% | ||
| 4 | FIBROGEN INC COM | 822,175 | 17,595,000 | 14.28% | ||
| 5 | Nabriva Therapeutics AG | 1,145,890 | 6,830,000 | 5.54% | ||
| 6 | CIDARA THERAPEUTICS INC | 495,050 | 5,149,000 | 4.18% | ||
| 7 | ESSA Pharma | 1,696,969 | 3,716,000 | 3.02% | ||
| 8 | Pieris Pharmaceuticals | 1,697,384 | 2,376,000 | 1.93% | ||
| 9 | EDITAS MEDICINE INCORPORATED | 66,162 | 1,074,000 | 0.87% | ||
| 10 | Dicerna Pharmaceuticals | 223,457 | 644,000 | 0.52% | ||
| 11 | CymaBay Therapeutics | 301,477 | 522,000 | 0.42% | ||
| 12 | Proteon Therapeutics | 0 | 0 | 0.00% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0000950123-17-001390, filed 2017.02.10).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
